




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 265/18, A61K 31/535	A1	(11) International Publication Number: WO 99/64405 (43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/US99/13199 (22) International Filing Date: 10 June 1999 (10.06.99) (30) Priority Data: 60/089,981 11 June 1998 (11.06.98) US (71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR-1ST18, Wilmington, DE 19807 (US). (72) Inventors: RADESCA, Lilian, A.; 203 Cheltenham Road, Newark, DE 19711 (US). MAURIN, Michael, B.; 28 Country Gates Road, Wilmington, DE 19810 (US). RABEL, Shelley, R.; 431 Buttonwood Drive, Landenberg, PA 19350 (US). MOORE, James, R.; 39 Flinthill Drive, Newark, DE 19702 (US). (74) Agent: VAN ATTEN, Mary, K.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: CRYSTALLINE EFAVIRENZ**(57) Abstract**

The potent reverse transcriptase inhibitor Efavirenz is produced in crystalline form. Crystalline Efavirenz exists in several physical forms which are designated Forms 1, 2, 3, 4 and 5 and are characterized by x-ray powder diffraction and differential scanning calorimetry. Pharmaceutical compositions and methods are useful for the treatment of the human immunodeficiency virus (HIV).